19 Nov 2026, 09:00
Director Interests—
Announcement history available from 1 August 2025
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 19 Nov 2026, 09:00 | Change of Director's Interest Notice - DW | Director Interests | — | 02009 | |
| 18 Nov 2026, 09:02 | Change of Director's Interest Notice - DW | Director Interests | — | 02009 | |
| 17 Nov 2026, 08:49 | Change of Director's Interest Notice - DW | Director Interests | — | 02009 | |
| 16 Nov 2026, 16:50 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 16 Nov 2026, 09:03 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 13 Nov 2026, 08:23 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 6 Nov 2026, 14:30 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 6 Nov 2026, 08:44 | Notification regarding unquoted securities - ALA | Securities Administration | — | 06021 | |
| 5 Nov 2026, 10:20 | Amended Constitution | Securities Administration | — | 12012 | |
| 4 Nov 2026, 14:36 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 4 Nov 2026, 10:35 | Correction to previous CEO appointment announcement | Company Administration | — | 12001, 12008 | |
| 4 Nov 2026, 10:23 | 2026 AGM Presentation | Presentations | — | 03026, 15001, 15002 | |
| 4 Nov 2026, 09:56 | Arovella Appoints CEO | Company Administration | MS | 12019 | |
| 29 Oct 2026, 08:36 | Complete tumour clearance in gastric cancer animal study | Company Update | — | 11001 | |
| 27 Oct 2026, 08:41 | First Patient Dosed with ALA-101 | Company Update | MS | 11001 | |
| 23 Oct 2026, 08:27 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 | |
| 22 Oct 2026, 08:43 | Arovella receives R&D tax rebate of $4.03 million | Periodic Reports | MS | 03014, 12008 | |
| 7 Oct 2026, 08:57 | Second Clinical Batch Released for Immediate Patient Use | Company Update | MS | 11001 | |
| 6 Oct 2026, 16:55 | Cell and Gene Innovation Spotlight Presentation | Presentations | — | 03026 | |
| 5 Oct 2026, 08:20 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08004, 08006 | |
| 1 Oct 2026, 13:54 | The path to first patient dosing | Company Update | MS | 11001 | |
| 17 Sept 2026, 08:56 | 2026 ESG Report | Periodic Reports | — | 03014, 12008 | |
| 9 Sept 2026, 08:21 | Notification of 2026 AGM Date | Meetings & Governance | — | 08006, 16002 | |
| 7 Sept 2026, 09:00 | Clinical manufacturing batch released, first site activated | Company Update | MS | 11001 | |
| 20 Aug 2026, 11:31 | Corporate Governance Statement | Company Administration | — | 03024 | |
| 20 Aug 2026, 11:28 | Appendix 4G | Company Administration | — | 03025 | |
| 20 Aug 2026, 11:27 | Appendix 4E and Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 17 Aug 2026, 11:59 | Notification regarding unquoted securities - ALA | Securities Administration | — | 06021 | |
| 12 Aug 2026, 13:11 | Investor Webinar Presentation | Presentations | — | 03026, 14014 | |
| 11 Aug 2026, 16:10 | Investor Webinar Registration | Presentations | — | 14014 | |
| 27 July 2026, 12:15 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 30 June 2026, 09:12 | Notice under Section 708A | Securities Administration | — | 06018 | |
| 30 June 2026, 09:08 | Notification of cessation of securities - ALA | Securities Administration | — | 06027 | |
| 30 June 2026, 09:06 | Application for quotation of securities - ALA | Securities Administration | — | 06020 | |
| 25 June 2026, 08:19 | First-In-Human Trial | Company Update | — | 11001 | |
| 10 June 2026, 09:09 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 9 June 2026, 14:01 | Turtle to Clinical Advisory Board&Fiorenza Lead Investigator | Company Administration | — | 12008 | |
| 26 May 2026, 09:26 | Notification of cessation of securities - ALA | Securities Administration | — | 06027 | |
| 8 May 2026, 08:33 | Notification of cessation of securities - ALA | Securities Administration | — | 06027 | |
| 7 May 2026, 10:20 | Final Director's Interest Notice x4 | Director Interests | — | 02010 | |
| 7 May 2026, 08:30 | Arovella Presents at ISCT Conference in Dublin | Company Update | — | 11001 | |
| 7 May 2026, 08:24 | Arovella Appoints Acting CEO | Company Administration | MS | 12019 | |
| 4 May 2026, 10:00 | Board Refresh and CEO Resignation | Company Administration | MS | 12001, 12017, 12019 | |
| 1 May 2026, 10:22 | Initial Director's Interest Notice x4 | Director Interests | — | 02008 | |
| 28 Apr 2026, 15:58 | Appointment of 4x Non-Executive Directors | Company Administration | — | 12001 | |
| 28 Apr 2026, 15:51 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 | |
| 27 Apr 2026, 08:54 | Notification regarding unquoted securities - ALA | Securities Administration | — | 06021 | |
| 23 Apr 2026, 08:30 | Notice Received Under Section 249D Withdrawn | Meetings & Governance | — | 08006, 12008 | |
| 23 Apr 2026, 08:21 | Proposed issue of securities - ALA | Securities Administration | — | 06013 | |
| 22 Apr 2026, 11:05 | Update Regarding Section 249D Notice | Company Administration | — | 12008 |